Anti-amyloidogenic activity of IgGs contained in normal plasma.
BACKGROUND
We have previously shown that a subpopulation of naturally occurring human IgGs has therapeutic potential for the amyloid-associated disorders. These molecules cross-react with conformational epitopes on amyloidogenic assemblies, including amyloid beta (Abeta) protein fibrils that are a pathological hallmark of Alzheimer's disease.


METHODS
Using our europium-linked immunosorbant assay, we established that approximately 95% of 260 screened donor plasma samples had amyloid fibril-reactive IgGs and Abeta conformer-reactive IgGs with minimal binding to Abeta monomers. Anti-amyloidogenic reactivity was diverse and attributed to Abeta targeting multiple fibril-related binding sites and/or variations in multidentate binding.


CONCLUSIONS
There was no correlation between anti-fibril and anti-oligomer reactivity and donor age (19 to 60 years old) or gender. These findings demonstrate the inherent but diverse anti-amyloidogenic activity of natural IgGs contained in normal plasma.


CONCLUSIONS
Our studies provide support for investigating the clinical significance and physiological function of this novel class of antibodies.
O'Nuallain
Brian
B
Human Immunology and Cancer Program, Department of Medicine, University of Tennessee Graduate School of Medicine, Knoxville, TN 37920, USA. brian.onuallain@ucd.ie
Williams
Angela D
AD
McWilliams-Koeppen
Helen P
HP
Acero
Luis
L
Weber
Alfred
A
Ehrlich
Hartmut
H
Schwarz
Hans P
HP
Solomon
Alan
A
D000328:Adult; D000544:Alzheimer Disease / Q000276:immunology / Q000628:therapy; D016229:Amyloid beta-Peptides / Q000276:immunology*; D000918:Antibody Specificity / Q000276:immunology; D000937:Antigen-Antibody Reactions; D003429:Cross Reactions; D004797:Enzyme-Linked Immunosorbent Assay; D000939:Epitopes / Q000276:immunology; D005260:Female; D006801:Humans; D007113:Immunity, Innate; D007074:Immunoglobulin G / Q000097:blood / Q000276:immunology*; D016756:Immunoglobulins, Intravenous / Q000276:immunology / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D010446:Peptide Fragments / Q000276:immunology*; D055815:Young Adult
D016229:Amyloid beta-Peptides; D000939:Epitopes; D007074:Immunoglobulin G; D016756:Immunoglobulins, Intravenous; D010446:Peptide Fragments; C078592:amyloid beta-protein (1-40); C075222:amyloid beta-protein (1-42)
Neurology. 2005 May 10;64(9):1553-62
15883316
J Neurosci Res. 2006 Aug 1;84(2):434-43
16767774
Neurosci Lett. 2004 Jan 30;355(3):226-30
14732472
Biochim Biophys Acta. 2004 Dec 24;1739(1):5-25
15607113
J Immunol. 2006 Jun 1;176(11):7071-8
16709869
Neurobiol Aging. 2004 Sep;25(8):1023-32
15212827
J Neurochem. 2007 Jun;101(5):1172-84
17286590
Biochemistry. 2008 Nov 25;47(47):12254-6
18956886
Curr Alzheimer Res. 2004 Aug;1(3):149-63
15975063
J Neurosci. 2008 Apr 16;28(16):4231-7
18417702
Biochem Biophys Res Commun. 1999 Apr 21;257(3):787-91
10208861
J Neurol Neurosurg Psychiatry. 2004 Oct;75(10):1472-4
15377700
Neurobiol Aging. 2009 Nov;30(11):1728-36
18294736
Cancer Biother Radiopharm. 2003 Dec;18(6):853-60
14969598
BMC Neurosci. 2007 Mar 20;8:22
17374155
Adv Intern Med. 2000;45:107-37
10635047
J Biol Chem. 2005 Apr 29;280(17):17458-63
15728175
Nature. 1992 Sep 24;359(6393):322-5
1383826
Brain Res. 2008 Jul 11;1219:169-79
18534566
Brain. 2003 Sep;126(Pt 9):1935-9
12821522